Asian Journal of Nuclear Medicine
亞洲核醫學雜志

Volume 2 Number 1, March 2002
Abstract

抗CD71人-鼠嵌合抗體(D2C)的體內腫瘤定位和抗體分佈研究

王 碩1,雷萍2,蔣琳1,曹衛3,朱慧芬2,崔武任2,王央貢2,董敏2,沈關心2
1江漢大學醫學與生命科學學院,武漢430016,中國
2華中科技大學同濟醫學院免疫學系,武漢430030,中國
3華中科技大學同濟醫學院附屬協和醫院核醫學科,武漢430022,中國

目的 研究抗CD71人-鼠嵌合抗體(D2C)的體內腫瘤定位和抗體分佈。方法 Balb/c(nu/nu)裸鼠背部皮下種植人肝癌細胞株(SMMC-7721),腫瘤直徑達0.5~1.5cm時,分別以腹腔注射和腫瘤基底局部注射方式給予131I-D2C抗體,對照組注射游離Na131I;注射後第1、3、7天分別進行SPECT顯像,7天後處死裸鼠,進行生物學分佈實驗,測量腫瘤組織(T)與非腫瘤組織(NT)放射性計數比值。結果 腹腔注射組,裸鼠腫瘤組織區域在顯像第3天出現高度放射性濃聚,並持續到第7天。而對照組,在24h可見代謝相關臟器濃聚,第3天明顯降低,第7天已接近本底水平;腫瘤基底局部注射131I-D2C組,24h後腫瘤局部放射性計數明顯高於體內其他組織。而對照組,3天後其放射性計數已明顯下降,無明顯器官組織濃聚;131I-D2C腹腔注射組和腫瘤局部注射組的T/NT值均大於2.0,但局部注射組部分臟器組織計數分佈明顯低於腹腔注射組,兩組間有顯著差異(P<0.05)。結論 全身或腫瘤局部使用嵌合抗體,在腫瘤組織局部均有特異性濃聚現象,而局部使用抗體時,體內其他組織的非特異性結合低於全身使用方式。

【關鍵詞】 CD71;人-鼠嵌合抗體;放射免疫顯像;免疫治療

In vivo tumor localization and biodistribution in the human tumor xenografts models of an anti-CD71 mouse/human chimeric antibody

Wang Shuo1, Lei Ping2, Jiang Lin1, Cao Wei3, Zhu Huifen2, Cui Wuren2, Wang Yanggong2, Dong Ming2, Shen Guanxin2
1College of Medicine and Life Science, Jianghan University, Wuhan 430016, China.
2Institute of Immunology, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China.
3Department of Nuclear Medicine, Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China.

Objective In order to investigate the tumor localization and biodistribution of the anti-CD71 mouse/human chimeric antibody (D2C). Methods The tumor localization and biodistribution of the chimeric antibody (D2C) were observed by labeling the chimeric Ab with radioiodine(131I) and injecting it into nude mice(Balb/c nu/nu) transplanted with human hepatocellular carcinoma cells (SMMC-7721). Results The labeled chimeric Ab (D2C), with intraperitoneal as well as tumor regional administration, was significantly localized in the tumor and the location of the tumor was successfully visualized by SPECT. The in vivo D2C Ab 's biodistribution of organs and tissues showed that non-specific binding in the tumor regional administration was lower than those in the intraperitoneal. Conclusion The human/mouse chimeric antibody (D2C) can exert in specific tumor localization in vivo and can be utilized for radio-immunoimaging.

Key Words: CD71; Human/mouse chimeric antibody; Radio-immunoimaging; Immunotherapy



Back to Previous Page